The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy (Q33959260)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

anti-retroviral agent

0 references

Debbie Kamwendo

5

object named as

Debbie Kamwendo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

object named as

Ralf Weigel

3

0 references

9

object named as

Joseph J Eron

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mina C Hosseinipour

1

object named as

Mina C Hosseinipour

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

object named as

Susan A Fiscus

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

4

object named as

Sam Phiri

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Joep J G van Oosterhout

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Neil Parkin

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Julie A E Nelson

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Johnstone Kumwenda

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1127-1134

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Scaling up antiretroviral treatment in resource-poor settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update of the drug resistance mutations in HIV-1: Spring 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAD.0B013E32832AC34E

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33959260&oldid=1868528816"